MedTrace Logo

Buprenorphine and Integrated HIV Care

NCT00317460 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2020-04-03

No results posted yet for this study

Summary

The purpose of this study is to examine the efficacy of providing two levels of psychosocial support along with buprenorphine/naloxone (BUP) maintenance to opioid dependent patients receiving their care in an HIV clinical care setting.

Conditions

  • Substance-related Disorders
  • Drug Addiction
  • Human Immunodeficiency Virus
  • AIDS
  • HIV Infections

Interventions

OTHER

Physician Management

Standard physician care

BEHAVIORAL

Counseling

Physician Management and Counseling

Sponsors & Collaborators

  • The New York Academy of Medicine

    collaborator OTHER

  • Yale University

    lead OTHER

Principal Investigators

  • Christopher J Cutter, Ph.D. · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2009-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00317460 on ClinicalTrials.gov